NGM·Healthcare·$992M·#34 / 520 in Healthcare
ETON Eton Pharmaceuticals, Inc.
74SOLID
CATEGORY BREAKDOWN
GROWTH100
QUALITY85
STABILITY69
VALUATION40
GOVERNANCE53
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+104.9%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
53.5%
75
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
118.6%
6
< 25% strong
Price / Sales
Market cap relative to trailing revenue
11.4x
40
< 3x strong
Rule of 40
Growth rate plus operating margin
104
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.4%
36
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.1%
87
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ETON WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ETON's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.